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Regulation of intracellular cyclic adenosine 3,5-mono-
phosphate (cAMP) is integral in mediating cell growth, cell
differentiation, and immune responses in hematopoietic
cells. To facilitate studies of cAMP regulation we developed a
BRET (bioluminescence resonance energy transfer) sensor
for cAMP, CAMYEL (cAMP sensor using YFP-Epac-RLuc),
which can quantitatively and rapidly monitor intracellular
concentrations of cAMP in vivo. This sensor was used to char-
acterize three distinct pathways for modulation of cAMP syn-
thesis stimulated by presumed Gs-dependent receptors for
isoproterenol and prostaglandin E2. Whereas two ligands,
uridine 5-diphosphate and complement C5a, appear to use
known mechanisms for augmentation of cAMP via Gq/cal-
cium and Gi, the action of sphingosine 1-phosphate (S1P) is
novel. In these cells, S1P, a biologically active lysophospho-
lipid, greatly enhances increases in intracellular cAMP trig-
gered by the ligands for Gs-coupled receptors while having
only a minimal effect by itself. The enhancement of cAMP by
S1P is resistant to pertussis toxin and independent of intra-
cellular calcium. Studies with RNAi and chemical perturba-
tions demonstrate that the effect of S1P is mediated by the
S1P2 receptor and the heterotrimeric G13 protein. Thus in
these macrophage cells, all four major classes of G proteins
can regulate intracellular cAMP.
Cyclic adenosine 3,5-monophosphate (cAMP), a ubiqui-
tous second messenger, mediates a wide range of cellular func-
tions including cell metabolism (1), cell proliferation and dif-
ferentiation (1), immune responses (2, 3), memory formation
(4), and cardiac contractility (5). Canonically, the concentration
of intracellular cAMP is regulated by two distinct families of
enzymes. The transmembrane adenylyl cyclases (ACs)3 synthe-
size cAMP from adenosine triphosphate (6, 7), whereas the
cAMP-specific phosphodiesterases metabolize cAMP to bio-
logically inactive adenosine 5-monophosphate (8, 9). ACs are
primarily activated by Gs but their activities can also be differ-
entially regulated by Gi, G, or Ca2 (10, 11). The activities
of various phosphodiesterases can be regulated by protein
kinase A (PKA), extracellular-regulated kinase (ERK), phos-
phoinositide 3-kinase, and the concentration of cAMP itself
(12–16). Thus integration of signaling by stimuli that can reg-
ulate the intracellular concentration of cAMP will depend
strongly on the various pathways and the subtypes of ACs and
phosphodiesterases expressed in individual cells at any given
time.
Assessment of the regulation of intracellular cAMP in vivo
has only become possible recently. Zaccolo et al. (17) first
described a FRET sensor for cAMP based on the cAMP binding
domain of PKA. Subsequently, several reports have described
FRET sensors for cAMP based on binding of the nucleotide to
the Epac proteins (18–21). While these FRET sensors have
been effective for measuring changes and localization of cAMP
in single cells, measurements are tedious. Furthermore, the
requirement for excitation of donor molecules produces a
range of problems including cell damage, photobleaching, and
low signal-to-noise ratios due to intrinsic cellular autofluores-
cence. This precludes use of the FRET sensors in high through-
put population assays. In contrast, BRET (bioluminescence res-
onance energy transfer) sensors use an enzymatic reaction to
produce energy emission in the donor, usually produce better
signal-to-noise ratios, and are better suited for high throughput
population assays (22). We report here the development and
characterization of an Epac-based BRET sensor for cAMP
(CAMYEL) with improved dynamic range and a method to
quantify intracellular cAMP changes.
This sensor was further used to characterize a novel phe-
nomenon identified in RAW 264.7 cells. The Alliance for Cel-
lular Signaling (AfCS) has conducted a comprehensive double
ligand screen using the mouse macrophage-like cell line, RAW
* This work was supported by National Institutes of Health Grant GM
62114, the Robert A. Welch foundation (to P. C. S.), and the Alfred and
Mabel Gilman Chair in Molecular Pharmacology (to P. C. S.). The costs of
publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental data and Figs. S1–S7.
1 To whom correspondence may be addressed: UT Southwestern Medical
Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9196. Tel.: 214-645-6105;
Fax: 214-645-6118; E-mail: lily.jiang@utsouthwestern.edu.
2 To whom correspondence may be addressed: UT Southwestern Medical
Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9196. Tel.: 214-645-6149;
Fax: 214-645-6118; E-mail: paul.sternweis@utsouthwestern.edu.
3 The abbreviations used are: AC, adenylyl cyclase; ISO, isoproterenol; PGE,
prostaglandin E2; C5a, complement C5a; S1P, sphingosine 1-phosphate;
CAMYEL, cAMP sensor using YFP-Epac-RLuc; EIA, enzyme-linked immuno-
assay; TER, terbutaline; BRET, bioluminescence resonance energy transfer;
FRET, fluorescence resonance energy transfer; RL,Renilla luciferase; SERCA,
sarcoplasmic reticulumcalciumATPase; ERK, extracellular signal-regulated
kinase; PKA, cAMP-dependent protein kinase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 282, NO. 14, pp. 10576–10584, April 6, 2007
Printed in the U.S.A.
10576 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 14•APRIL 6, 2007
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on June 15, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
 http://www.jbc.org/cgi/content/full/M609695200/DC1
Supplemental Material can be found at: 
264.7, to examine the extent of ligand interactions on a variety
of downstream outputs, including cAMP (23). One of the strik-
ing results is the interaction between the lysophospholipid,
sphingosine 1-phosphate (S1P), and ligands for receptors that
stimulate cAMP. S1P alone does not significantly elevate either
cAMP or Ca2 in RAW 264.7 cells. However, S1P greatly
increases the amount of intracellular cAMP stimulated by iso-
proterenol (ISO) and prostaglandin E2 (PGE). Other ligands
that stimulatemobilization of Ca2 in RAW264.7 cells, such as
complement C5a and uridine 5-diphosphate (UDP), also
enhance stimulation of cAMP by ISO and PGE, but are less
efficacious than S1P.
Receptors for S1P, formerly known as endothelial differenti-
ation genes (Edg), are heptahelical transmembrane receptors
that can variously interact with at least three G protein subfam-
ilies, Gi, Gq, and G12/13 (25–27), to affect regulation of
phospholipase C (Gi and Gq), phosphoinositide 3-kinase
(Gi), and guanine nucleotide exchange factors for Rho
(G12/13) (28–33). S1P has also been shown to regulate inhibi-
tion of intracellular cAMP by a receptor-dependent Gi-medi-
ated mechanism (29, 31, 32). Although S1P has been shown to
stimulate intracellular cAMP in cells overexpressing S1P recep-
tors, there is no evidence that the S1P receptors couple directly
to Gs and the mechanism remains unclear (30).
Using the CAMYEL sensor, we identified roles for S1P2
receptors andG13 proteins inmediating the synergistic effect of
S1P on cAMP responses. This is the first evidence that a G13
pathway is involved in the regulation of cAMP. Kinetic experi-
ments indicate that the effect of S1P has rapid onset and works
through increasing the rate of synthesis of the cyclic nucleotide.
EXPERIMENTAL PROCEDURES
Reagents—Isoproterenol, prostaglandin E2, complement
C5a, uridine 5-diphosphate, 8-bromo cAMP, and phosphodi-
esterase inhibitors (Sigma), sphingosine 1-phosphate (Avanti
Polar Lipids), terbutaline (Sigma), ICI 118551 (Biomol
Research), SEW2871 (Cayman Chemical), and JTE 013 (Tocris
bioscience) were purchased from the sources indicated.
DNA Constructs—Epac1 (amino acids 148–881) was gener-
ated by RT-PCR with human brain RNA as template using the
primer pair 5-CTC CGC GGA CCC GAG CCC GTG GGA
ACT C-3 and 5-GTG AAT TCT GGC TCC AGC TCT CGG
GAG AG-3. Two point mutations, T781A and F782A, which
eliminate the guanine nucleotide exchange activity of Epac (21),
were created using site-directed mutagenesis with the
QuikChange kit from Stratagene. Citrine with the monomeric
mutation A206K and Renilla luciferase (RL) were amplified by
PCR using primer pairs: 5-ATG GAT CCA TGG TGA GCA
AGG GCG AG-3 and 5-CCG CGG AGC TTG TAC AGC
TCG TCC ATG-3; 5-GAA TTC ATG GCT TCC AAG GTG
TAC G-3 and 5-GCG GCC GCT TAC TGC TCG TTC TTC
AGC-3. Fragments were then fused to the N and C termini of
Epac1 as shown in Fig. 1. Circularly permuted citrine was gen-
erated by sewing PCR; constructs were equivalent to those
described for the improved YFP, Venus (34). pcDNA3.1-His
from Invitrogen was used for expression in mammalian cells;
pQE30 from Qiagen was used for expression in bacteria. The
pFB-neo vector from Stratagene was used to deliver the cAMP
sensor into RAW 264.7 cells via retroviral infection.
Cell Culture andTransfection—Protocols for culturing RAW
264.7 cells and for transfection of DNA and siRNA or retroviral
infection can be found at the AfCS website. Briefly, RAW 264.7
cells (obtained fromATCC) andHEK293 cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, and 20 mM NaHEPES,
pH 7.4. Transfection with DNA was carried out using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. Retrovirus was made with the Phoenix Amphotropic
packaging cell line (Orbigen). Infection of RAW cells was initi-
ated by applying virus-containing supernatant harvested from
the packaging cell line with 6 g/ml polybrene on top of the
cells and spinning at 1,200 g at 32 °C for 2 h. Cells were then
cultured with the viral supernatant for 1 day at 32 °C followed
by removal of the viralmedium and further culturingwith fresh
medium containing 500 g/ml G418 at 37 °C.
GeneKnockdownbyRNAi—siRNApools of oligomers target-
ing S1P1, S1P2, and G13 were SMARTPool products pur-
chased from Dharmacon. The sequence for the S1P2-B oli-
gomer (5-GCA TGT CAC TCT GTC CTT A-3) is unique
from those in the SMARTPool. RAW cells were transfected
with 400nM siRNAusing Lipofectamine 2000.Cellswere plated
into 96-well tissue culture plates at 24 h post-transfection and
assayed at 48-h post-transfection. Samples were taken for
Western blot or qRT-PCR to assess the knockdown level of
protein or mRNA, respectively. Cells were lysed and blotted
with antiserum B-860 to detect G13 as described (35). Respec-
tive primers for qRT-PCR of the S1P1 and S1P2 receptors are:
(F) 5-CGG TGT AGA CCC AGA GTC CTG-3 and (R)
5-TTC TTT TAT GGA GCT TTT CCT TGG-3; (F) 5-AGC
CAACAGTCTCCAAAACCA-3 and (R) 5-GGGCTGAGC
ACTGGCTAGG-3. The qRT-PCR reactions were done with
an ABI 7500 Real-Time PCR system from Applied Biosystems.
EIAAssay for cAMP—Cells were plated on 96-well tissue cul-
ture plates 1 day prior to the treatment with ligands. Prior to
treatments, cells were cultured in serum-free medium for 1 h.
Ligands were then added to stimulate the cells. After the addi-
tion of ligands, reactions were stopped at the indicated times by
removal of medium and cell lysis with 65% ethanol. Cell lysates
were then dried and assayed using the cAMP Biotrak EIA kit
(Amersham Biosciences).
Measurement of Fluorescence in Vitro—Cells that express the
CAMYEL sensor were lysed with buffer containing 20 mM
NaHEPES, pH 7.4, 50 mM KCl, 50 mM NaCl, 2.5 mM MgCl2,
0.2% Nonidet P-40, 5 mM dithiothreitol, and a mixture of pro-
tease inhibitors (Roche Applied Science). Bacterial expressed
protein with an N-terminal His6 tag was purified with Ni-NTA
resin. Coelenterazine-h (2M final concentration)was added to
the cell lysates or purified proteins immediately prior to meas-
urements of fluorescence emission spectra using a Spectroflu-
orometer MD-5020 (Photon Technology International).
Assay of BRET in Live Cells—Cells were plated in 96-well
solid white tissue culture plates (Greiner) at a density of 60,000
cells per well the day before assays. Cells were serum-starved in
Hank’s balanced salt solution, pH 7.4, for 1 h before treatments.
The BRET assay was carried out with a POLARstar Optima
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plate reader fromBMGLabTech. Emission signals fromRL and
YFP were measured simultaneously using a BRET1 filter set
(475–30/535–30). Cells in each well were assayed in 80 l of
Hank’s balanced salt solution with 2 M coelenterazine-h, and
stimulations were initiated by injection of 20 l of 5 ligand.
Calculation of cAMP Concentration—Ratiometric data were
converted to cAMP concentration using Equation 1.
cAMP Kd R RminRmax R (Eq. 1)
The Kd and Hill coefficient for association of cAMP with the
sensorwere determined to be 8.8Mand 1, respectively.R is the
intensity ratio of RL to YFP. Rmax is obtained by adding 2 mM
8-bromo cAMP to the cells at the end of the assay. Rmin is
arbitrarily set to be the average ratio of measurements with
unstimulated cells minus 4 S.D. (see supplementary data for
details).
RESULTS
An Epac-based BRET Sensor for cAMP-CAMYEL—Several
FRET sensors for detection of cAMP have been described in
recent articles (19–21). Because the sensor containing an inac-
tive cytosolic mutant form of human Epac-1 appeared to have
the best signal-to-noise ratio (21), it was used as a basis for
development of a BRET sensor. The design of the sensor is
shown in Fig. 1A; it utilizes the enhanced variant of YFP, citrine
(36), and Renilla luciferase as the BRET pair with human Epac1
inserted in between. Spectra of the expressed sensor protein
revealed strong resonance energy transfer that was significantly
reduced in response to cAMP, as expected from the FRET sen-
sors and known structural changes in the molecule (21, 37, 38).
We sought to further improve the signal by replacing citrine
with circularly permuted versions of the protein. Such circular
permutations of the fluorescent proteins have been shown to
vastly improve the FRET signal in a sensor for calcium (34).
This improvement in FRET efficiency may be due to altered
fluorophore orientation of the permuted proteins, and we rea-
soned that similar changes would apply to the efficiency of
BRET sensors. Of the five different circular permutations
screened, we found that replacement of citrine with citrine-
cp229 improved the changes of BRET ratio uponbinding cAMP
by 2-fold (Fig. 1). The improved sensor gives an increase in
BRET ratio (Rluc/YFP) of about 70% with cAMP and was
named CAMYEL (cAMP sensor using YFP-Epac-RLuc).
TheCAMYEL protein was expressed in bacteria and purified
for further characterization. A concentration response analysis
with cAMP indicated aKd and n (Hill coefficient) for binding of
8.8M and 1, respectively (supplemental Fig. S1); these are sim-
ilar to binding properties reported for the FRET sensor (21).
While the activity of luciferase can be influenced by calcium,
resonance energy transfer should be independent of these
changes in absolute signals if calcium does not cause any con-
formational changes in the sensor protein. This appears to be
the case because the BRET ratios, either in the presence or
absence of cAMP, were not influenced by concentrations of
calcium up to 1 mM (supplemental Fig. S2). Additional experi-
ments indicated that the BRET signalswere also independent of
changes in pHwithin the tested range (pH 6.5–8.0, supplemen-
tal Fig. S2). The response time of the sensor was assessed by
measured changes in BRET when the sensor was exposed to
abrupt increases or decreases in cAMP. Such changes depend
on both the association and dissociation of cAMP and the ensu-
ing changes in conformation. In vitro, the change of BRET ratio
in response to altered cAMPconcentrations appears to be com-
plete within 1 to 2 s (supplemental Fig. S3). This rate of signal
change is well suited for measuring the kinetics of change in
intracellular concentrations of cAMP.
Regulation of Cytosolic cAMP in RAW 264.7 Cells—One of
the outputs measured in a survey by the Alliance for Cellular
Signaling for the complexity of interactions among signaling
pathways was the regulation of the classical second messenger,
cAMP. A traditional enzyme-linked immunoassay (EIA) for
total intracellular cAMP was used to identify two ligands, iso-
proterenol (ISO) and prostaglandin E2 (PGE), which effectively
increased this second messenger in RAW cells. These two
ligands were subjected to a comprehensive double ligand
screen with over twenty additional ligands to look for non-ad-
ditive interactions (23). Ligands that elicit calcium responses in
RAW cells, such as complement C5a and uridine 5-diphos-
phate (UDP), enhanced cAMP responses triggered by ISO or
PGE. Interestingly, S1P, which at best induced only minimal
cAMP or calcium responses in RAW cells by itself, enhanced
the cAMP response to the ISO or PGE by 2–3-fold (Fig. 2A). To
study these synergistic interactions in detail, cell lines that sta-
bly express the sensor for cytosolic cAMP, CAMYEL, were
derived from RAW 264.7 cells. The level of expression of the
CAMYEL sensor in the RAW 264.7 cells was estimated to be
about 100 nM based on comparativeWestern blots. These cells
FIGURE 1. An Epac-based BRET sensor for cAMP (CAMYEL). A, schematic
drawing of the domain structure of CAMYEL. The inactive cytosolic mutant
formof humanEpac-1 (amino acids 149–881, T781A, F782A) (21)was flanked
by citrine or a circularly permuted citrine-cp229 and Renilla luciferase (RL).
B and C, comparison of emission spectra of Citrine-Epac-RL (B) and Citrine-
cp229-Epac-RL (C) in the presence and absence of 100M cAMP. HEK293 cells
were transiently transfected with either construct. Cells were lysed with
buffer containing 20 mM NaHEPES, pH 7.4, 50 mM KCl, 50 mM NaCl, 2.5 mM
MgCl2, 0.2% Nonidet P-40, 5mM dithiothreitol, and protease inhibitors. Emis-
sion spectra were measured in the presence of 2 M coelenterazine-h sub-
strate with or without 100 M cAMP.
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produced normal calcium and cAMP (as measured by EIA)
responses to an array of ligands. In such cell lines the BRET
ratio, RLuc/YFP, can then be used to continuously monitor
intracellular cAMP in real time (Fig. 2B). The dynamic range of
the sensor in RAW cells was measured using 2 mM 8-bromo
cAMP, a cell-permeable analog of cAMP, to saturate the sensor
in vivo.
Stimulation of -adrenergic receptors with ISO led to rapid
decreases of the BRET signal hence increases of the fluores-
cence intensity ratio, Rluc/YFP (Fig. 2B). The response peaked
at20–30 s after addition of ligand and declined to a sustained
level. This response profile is qualitatively the same as meas-
ured by EIA. The BRET sensor also recapitulates the effect of
S1P andUDPonproduction of cAMP.Addition of either S1Por
UDP alone elicited minimal cAMP responses (Fig. 2B),
although UDP stimulates robust increases in intracellular cal-
cium in RAW cells. This confirms in vitro results that calcium
does not affect theBRET ratio of the sensor. Simultaneous addi-
tion of either S1P or UDP together with ISO led to greater
changes in BRET at the peak of the response and subsequent
decreases over time to a sustained level that was equivalent to
that obtained with the addition of ISO alone.
To better assess the dynamics of changes in intracellular
cAMP, we converted the ratiometric results shown in Fig. 2B to
concentrations of cAMP (Fig. 2C, see “Experimental Proce-
dures” and supplementary information). Using this method of
conversion, we can then compare quantitative changes in
cAMP measured with the BRET sensor to those obtained with
the EIA. As shown in Fig. 2C, S1P or UDP synergistically
increases the peak cAMP response induced by ISO alone by
2–4 or 1.5–2 folds, respectively. This slightly higher ratio of
enhancement than that observed with EIA is likely due to two
differences in the assessments. First, the peak response is usu-
ally missed by the EIA. Second, the sensor measures free intra-
cellular cAMP, whereas the EIA also measures bound nucleo-
tide that will be proportionally higher at lower concentrations.
Enhancement of cAMP by S1P Is Caused by Increased Synthe-
sis of cAMP—Use of the CAMYEL sensor allows us to dissect
the effect of S1P on cAMP through detailed kinetic measure-
ments. The intracellular concentration of cAMP is determined
by a dynamic balance between its biosynthesis via adenylyl
cyclases and its degradation by phosphodiesterases. The
enhancement observed with S1P could be due to either stimu-
lation of synthesis or inhibition of degradation. We first com-
pared rates of cAMP increases when cells were stimulated by
either ISO alone or combination of ISO and S1P. The synergis-
tic effect of S1P is observed at the earliest times after ligand
addition with a greater than 4-fold increase in rate throughout
the approach to peak values (Fig. 3, filled symbols). This sug-
gests that the enhancement by S1P is temporally well-coupled
to the early processes causing activation of ACs.
Inhibitors of phosphodiesterases were then used to reduce
degradation of cAMP. Under these conditions, ISO produced a
much greater rise in intracellular cAMP, which was readily sus-
tained over longer times. However, blocking degradation of
cAMP did not reduce the enhanced rate or the extent of cAMP
accumulation affected by S1P (Fig. 3, open symbols). Similar
results were obtained with PGE, and its combination with S1P
(data not shown). These results clearly indicate that modula-
tion of phosphodiesterase activity is not a primary mechanism
by which S1P enhances cAMP.
FIGURE 2. Measurement of intracellular cAMP responses in RAW 264.7
cells. A, changes in cAMP measured by EIA. At time 0, cells were stimulated
with16 nM ISO, 16 nM ISO and 0.5 M UDP, 16 nM ISO and 10 nM S1P, or 50 nM
S1P as indicated. At the given times, reactions were stopped by removal of
medium and addition of cell lysis solution, and cAMPwas determined by EIA.
The results shown are the average of three independent experiments done
with two different preparations of cells: the variance among the experiments
is about 30% of the signals. B, measurement of cAMP responses using the
CAMYEL sensor. Emission ratios (RL/YFP) were measured in RAW 264.7 cells
stably expressing theCAMYEL sensor. Cellswere stimulated at time0by addi-
tionof either 16nM ISO16nM ISOand0.5MUDP, 16nM ISOand10nMS1P, 10
nM S1P, 2.5MUDP, or 2mM8-bromo cAMP as indicated. C, ratiometricmeas-
urements of CAMYEL responses were converted to intracellular concentra-
tions of cAMP.
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Stimulation of cAMP by S1P Is Related to the Activities of the
Gs Pathway—When RAW cells expressing the CAMYEL sen-
sor are treated with ISO, the cells rapidly increase the level of
free intracellular cAMP to a peak response (20–30 s); this is
usually followed by a rapid decrease to a sustained response that
declines slowly over time. To examine the temporal coupling
between the effect of S1P and activation of the Gs pathway, S1P
was added either simultaneously with ISO or during the sus-
tained phase of the ISO response (Fig. 4A). Interestingly, the
synergistic effect of S1P on intracellular cAMP was observed
throughout the experiment. Moreover, the increase in cAMP
induced by addition of S1P is directly related to the concentra-
tion of intracellular cAMP stimulated by ISO at the time of S1P
addition (Fig. 4B). Thus, the relative enhancement by S1P, a
maximal increase of about 300% over the stimulation produced
by ISO alone, remained the same regardless of when the ligand
was added after ISO. This indicates that not only can S1P exert
its effect as long as the synthetic pathway for cAMP is active,
but also themechanism for the effect of S1P is not altered by the
magnitude of cAMP synthesis activated byGPCR-Gs pathways.
The dependence of the S1P effect on the synthetic pathway of
cAMP was further tested by termination of stimulation of the
-adrenergic receptor with a specific antagonist, ICI-118551.
For this study, the agonist terbutaline (TER), which has a lower
affinity and faster rate of dissociation than ISO, was used. As
shown in Fig. 4C, S1P enhanced the cAMP response triggered
by TER as it did to that of ISO. Addition of ICI-118551 led to a
rapid decline of intracellular cAMP that had been stimulated by
TER (green trace, inverted triangles). Simultaneous addition of
ICI-118551 and S1P greatly reduced the effect of S1P in tandem
with inhibition of TER although transient enhancement was
observed (red trace, open circles). If the addition of ICI-118551
preceded that of S1P by 12 s, the effect of S1P was abolished
(green trace, inverted triangles). Therefore the S1P effect
requires activation of the Gs pathway and adenylyl cyclase.
Because the adenylyl cyclase activity in the RAW cells is unre-
sponsive to forskolin, a simple requirement for active adenylyl
cyclase could not be tested.
Enhancement of cAMP by UDP and C5a Is Mediated by Cal-
cium and Gi Pathways, Respectively—The activity of adenylyl
cyclases can be regulated by calcium and the Gi pathway (11).
To examine the role of calcium in the enhancements of cAMP
by UDP, C5a, and S1P, intracellular and extracellular calcium
FIGURE 3. Effect of S1P on intracellular cAMP has a fast onset and is not
affected by inhibitors of phosphodiesterases. The CAMYEL sensor was
used tomeasure the rise in cAMPwhencellswere treatedwith 16nM ISOor 16
nM ISO and 10 nM S1P either in the absence or in the presence of the phos-
phodiesterase inhibitors (PDEi), 10 M Ro20–1724 and 40 M isobutylmeth-
ylxanthine. Ligands were added at time 0, PDEi were added 2 min prior to
ligand addition, which was sufficient to cause maximum impact of the
inhibitors.
FIGURE 4. Effect of S1P on cAMP parallels activation of Gs. A, changes in
cAMPweremeasuredwith CAMYEL; cells were treatedwith 16 nM ISO at time
0 followed by addition of 10 nM S1P at the indicated times. B, effect of S1P on
intracellular cAMP is expressed as the ratio of the S1P induced peak of cAMP
to the concentration of cAMP induced by ISO alone at the time of S1P addi-
tion. For simultaneous addition of ISO and S1P the ratio is calculated as the
peak induced by the two ligands versus that by ISO alone. The synergistic
effect of S1P on cAMP appears to be the same throughout the 7 min assay
period. C, termination of -adrenergic receptor signaling diminished the
effect of S1P. All cellswere treatedwith 2.5MTER at time0. Additionof 10nM
S1P at 30 s greatly enhanced the cAMP response stimulated by TER (cyan, x).
Simultaneous additionof 10nMS1P and10M ICI 118551 (ICI), a-adrenergic
antagonist, greatly reduced the ability of S1P to affect increases in cAMP (red,
E). Addition of 10 M ICI 118551 at 30 s immediately initiated a decline in
cAMP; subsequent addition of 10 nM S1P 12 s later produced no effect on
intracellular cAMP concentration (green, ƒ).
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were depleted by addition of the SERCA inhibitor thapsigargin
and calcium chelator EGTA. The synergistic effects of S1P,
UDP or C5a on cAMP responses induced by ISO were assessed
with a sequential ligand format where addition of the enhanc-
ing ligands triggers a second peak response after the initial
response of cAMP to ISO (Fig. 5). Attenuation of intracellular
calcium did not affect the first cAMP response peak induced by
ISO, nor did it significantly affect the second peak response
triggered by S1P or C5a (Fig. 5, A and C). However, the
enhancement by UDP was largely ablated without intracellular
calcium (Fig. 5B).
Inactivation of the Gi pathway was achieved by treatment of
the cells with pertussis toxin. As shown in Fig. 5, inactivation of
the Gi pathway effectively ablated the effect of C5a on cAMP
without significantly affecting the cAMP response of ISO alone
(Fig. 5C) or the synergistic effects of UDP and S1P (Fig. 5,A and
B). In contrast to UDP and C5a, the stimulation of cAMP
observed with S1P could not be explained by these known
mechanisms.
The S1P2 Receptor Mediates the Changes in cAMP Caused by
S1P—RAW 264.7 cells express two receptors for sphingosine
1-phosphate, S1P1 (Edg1) and S1P2 (Edg5), as determined by
RT-PCR. A knockdown approachwith RNAiwas used to deter-
mine which receptor is responsible for mediating the effect of
S1P. Pools of four different siRNAoligomers specifically target-
ing either S1P1 or S1P2 were transfected into RAW cells carry-
ing the CAMYEL sensor. The effects of gene specific knock-
down were assessed by qRT-PCR (Fig. 6A). Knockdown of the
S1P2 receptor greatly reduced the synergistic effect of S1Pwith-
out changing the cAMP response triggered by ISO alone. This
phenotype is evident with either simultaneous addition of ISO
and S1P (Fig. 6C) or sequential addition of ISO followed by S1P
(Fig. 6D). A single siRNA oligomer (S1P2-B) that targets S1P2
was selected independently of the oligomer pool and used to
confirm the specificity of the S1P2 knockdown phenotype (Fig.
6D). A partial knockdown of S1P1 appeared to slightly enhance
the synergistic response of cAMP to S1P.However, the enhanc-
ing effect appeared to be nonspecific as an increase was also
observed when the cells were stimulated with the combination
of ISO and UDP (Fig. 6B).
The receptor knockdown result was further confirmed by
drug perturbations. SEW2871 is an agonist for the S1P1 recep-
tor (39). Addition of SEW2871 following that of ISO failed to
reproduce the effect of S1P (Fig. 6E). However, addition of JTE-
013, an antagonist for the S1P2 receptor (40), at 12 s prior to S1P
addition greatly reduced the effect of S1P on the cAMP
response triggered by ISO (Fig. 6F). Together these results indi-
cate that S1P preferentially uses the S1P2 receptor to enhance
intracellular concentrations of cAMP in RAW cells.
Stimulation of cAMP by S1P Is Mediated by G13—Whereas
S1P1 is reported to couple primarily to Gi (31, 32), S1P2 can act
through Gi, Gq, and G12/13 to stimulate a variety of pathways
(30, 31, 33). Because inactivation of the Gi pathway did not
attenuate the S1P effect on cAMP and the lack of calcium
response to S1P indicates that activation of Gq is unlikely, we
explored the potential role of G13 in the S1P synergism. As
shown in Fig. 7, transfection of cells expressing the CAMYEL
sensor with siRNAs targeting G13 greatly reduced the
enhancement of S1P on the cAMP response generated by ISO
(Fig. 7, C and D). In contrast, the response of cAMP to ISO
alone or its enhancement by UDP, a ligand which likely acts
through a Gq-coupled mechanism, remained unaffected (Fig.
7B). The enhanced effect of S1P on the cAMP response of PGE
was also attenuated by the knockdown of G13 (Fig. 7E).
The specificity of G13 involvement in the S1P synergy on
cAMP was assured by using a micro-RNA based shRNA deliv-
ered via retroviral infection to knockdown G13. The targeting
sequence was selected independently of the pooled oligomers,
and a similar phenotype was observed when cAMP was meas-
ured either with the CAMYEL sensor or an EIA (supplemental
Fig. S5). The partial reduction of the response is consistent with
an incomplete knockdown of the G13, but could also be indic-
FIGURE 5. Effect of intracellular calciumand activity of theGi pathway on
cAMP responses to dual ligands in RAW 264.7 cells. Cells expressing the
CAMYEL sensor were treated with 50 ng/ml pertussis toxin for 20 h or 1 M
thapsigargin and 2 mM EGTA for 2 min as indicated prior to ligand additions.
cAMP responses were induced by addition of 16 nM ISO at time 0 followed by
addition of 10 nM S1P (A), 0.5MUDP (B), or 100 nM C5a (C). Results shown are
averages from at least three experiments, error bars represent the S.D.
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ative of contributions from a second pathway. Attempts to
assess potential involvement of the most obvious candidate,
G12, have been hampered by our inability to produce effective
knockdown of this  subunit in RAW cells.
FIGURE 6. The S1P2 receptor transduces signaling by S1P formodulation
of intracellular cAMP. A, RAW cells expressing CAMYEL were transiently
transfected with control siRNA or pools of four siRNA oligomers (designated
as –P) targeting either the S1P1 or S1P2 receptor. Analysis by qRT-PCR showed
specific but partial knockdowns of the S1P1 and S1P2 receptors. B–D, cells
were assayed for cAMP responses to simultaneous addition of 16 nM ISO and
0.5 	 UDP (B), simultaneous addition of 16 nM ISO and 10 nM S1P (C), and
sequential addition of 16 nM ISO followed by 10 nM S1P (D). Knockdown of
S1P2 using a single oligomer (S1P2-B) that is independent of the pool of four
oligomers resulted in a similar phenotype (D). E, additionof 1MSEW2871, an
agonist for the S1P1 receptor, at 2 min after addition of ISO failed to induce a
synergistic cAMP response. F, addition of 100 nM JTE-013, an antagonist of
S1P2 receptors, at 12 s prior to addition of S1P significantly reduced the syn-
ergistic effect on cAMP. Ligands were added at time 0 or as indicated. Error
bars represent the S.D. of results from four experiments of 2 independent
transfections. Errors were similar for the other traces but left out for clarity.
FIGURE 7. G13 is required for the synergy of S1P on Gs-mediated cAMP
responses. A, RAW cells expressing CAMYEL were transiently transfected
with control siRNA or a pool of four siRNA oligomers (designated as –P) spe-
cifically targeting G13. The presence of G13 was assessed by Western blot.
The reduction of the -subunit in cells treated with four siRNA oligomers
targeting G13 was about 60%. B–D, response of cAMP in control transfected
and G13 knockdown cells to simultaneous addition of 16 nM ISO and 0.5 M
UDP (B), simultaneous addition of 16 nM ISO and10nMS1P (C), and sequential
addition of 16 nM ISO followed by 10 nM S1P (D). E, synergy of S1P on intracel-
lular cAMP induced by PGE is also reduced in G13 knockdown cells. Ligands
were added at time 0 or as indicated. Error bars represent the standard devi-
ation of results from four experiments of 2 independent transfections. Errors
were similar for the other traces but left out for clarity.
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DISCUSSION
We successfully converted an Epac-based FRET sensor for
cAMP to a BRET sensor. The signal of the new sensor was
improved 2-fold by using circularly permuted fluorescent pro-
teins, a technological advance used previously to alter the effi-
ciency of resonance energy transfer between FRET pairs (34).
The use of circularly permuted citrine in CAMYEL demon-
strates the utility of this method for evolving better sensors
using bioluminescent donors as well. With its good signal-to-
noise ratio and excellent dynamic range, CAMYEL is ideal for
continuous in vivo monitoring of cAMP metabolism in popu-
lations of cells.
The use of permeable cAMP analogs to saturate output fur-
ther allows calibration of the sensor and conversion of ratio-
metricmeasurements to real estimates of cAMPconcentration.
Its rapid and reversible response makes the sensor an excellent
tool tomeasure the kinetics of this signaling pathway and hence
supportmolecularmodeling of this signaling system, one of the
goals of theAlliance forCellular Signaling. The use ofCAMYEL
for exploring regulation of signaling pathways is described
herein. The sensor also has the potential to support high
throughput genome-wide genetic screens, such as an RNAi
screen, to identify new players involved in the regulation of
cAMP as well as screens for small molecule drugs.
The BRET sensor was used to characterize the cAMP
responses to dual ligands in mouse macrophage-like RAW
264.7 cells. Three ligands, which do not stimulate cAMP by
themselves, were found to enhance production of cAMP
induced by Gs-coupled receptors via three distinct mecha-
nisms. The effects of UDP and C5a on cAMP responses are
likely due to canonical regulation of adenylyl cyclase activity via
calcium regulated by Gq proteins and the Gi pathway, respec-
tively. Interestingly, the ability of S1P to enhance cAMP pro-
duction stimulated by Gs-coupled ligands uses neither of these
known pathways. Rather, S1P acts through S1P2 receptors and
uses the heterotrimeric G13 proteins to couple to the synthesis
of cAMP. This is the first evidence that a member of the G12/13
subclass of G proteins can robustly regulate production of this
classic and ubiquitous second messenger.
One remaining issue is to identify the site of action for stim-
ulation of cAMP synthesis by the S1P/G13 pathway. Three pos-
sible sites of action are the stimulatory receptors, Gs, or direct
action on adenylyl cyclases. Enhancement of the action of -
adrenergic receptors on Gs, perhaps facilitated by oligomeriza-
tion of receptors or modification of receptors, would likely be
accompanied by a shift in the concentration response curve of
ISO to a lower EC50 in the presence of S1P. However, the EC50
of the ISO response remained the same, regardless of S1P (sup-
plemental Fig. S4). In addition, the S1P/G13 pathway also syn-
ergistically stimulates cAMP triggered by PGE. This would
require the S1P/G13 pathway to somehow couple with both the
-adrenergic and prostaglandin receptors. Enhancement of the
activity of Gs by the S1P/G13 pathway would require pre-acti-
vation of Gs as S1P by itself does not activate Gs. Examples of
such regulation are not known but mechanisms might include
inhibition of the GTPase activity of Gs in analogy to the action
of cholera toxin. This seems unlikely because the Gs pathway is
common to all cells and this enhancement of cAMP synthesis
by S1P/G13 is not observed inmany other cells (such asHEK293
andHeLa) where S1P activates G13 (data not shown). Themost
likely target is one ormore subtypes of adenylyl cyclase, because
specific subtypes have already been described that account for
the impact of calcium and Gi. RAW 264.7 cells minimally
express four adenylyl cyclases, AC2,AC3,AC7, andAC9,where
AC2 could account for the Gi-dependent effects of C5a via a 
mechanism andAC3 could respond to stimulation via calcium/
calmodulin. We are in the process of determining the role of
each of these cyclase subtypes in the cAMP response of RAW
cells to hormonal stimuli.
Ahint to themechanismof S1P synergymay be evident in the
brief but significant increase in cAMP when S1P and the -
adrenergic antagonist were added to cells stimulated with TER
(Fig. 4C). In the absence of S1P, the antagonist initiates an
almost immediate decline in cAMP, suggesting rapid dissocia-
tion of TER from the receptor and coincident inactivation of
the receptor and adenylyl cyclase. When S1P was added simul-
taneously with the antagonist, there was an immediate increase
in cAMP that lasted about 10 s before the second messenger
started to decline. This indicates that adenylyl cyclase was not
rapidly inactivated under this condition and suggests S1P can
act rapidly by some mechanism to increase the lifetime of acti-
vated adenylyl cyclase, either by itself or in complex with Gs.
How does the G13 pathway regulate cAMP synthesis? Con-
ceivably, release of the  subunits from G13 could account for
the enhancing activity of S1P in a fashion similar to that of 
subunits released fromGi to regulate the activity of ACs (10, 11,
41, 42). Alternatively, G13 could act directly on adenylyl
cyclase. No evidence for this has yet been generated in attempts
to reconstitute the phenomena with cellular membranes and
activated G13 proteins (data not shown). A well-characterized
pathway stimulated by G13 is Rho-dependent regulation of
cytoskeleton and gene transcription (43, 44). We used inhibi-
tors of Rho and Rho kinases to block this pathway but failed to
disrupt the S1P synergy (supplemental Fig. S6). At this time,
further elucidation of mechanism will likely require identifica-
tion of additional players in the pathway. Use of the CAMYEL
sensormakes it possible to screen for such a player in a genome-
wide high throughput fashion.
What is the physiological relevance of this S1P/G13 effect in
intracellular cAMP regulation? To begin answering this ques-
tion, we examined the cAMP responses in primary macro-
phages derived from mouse bone marrow. The application of
S1P robustly enhanced the stimulation of cAMP production
observed with agonists of Gs-coupled receptors and its effect
appears to be prolonged into the sustained phase of the cAMP
response (supplemental Fig. S7). Interestingly, a similar phe-
nomenon of enhancement on cAMP responses has been
reported for thrombin in a human erythroleukemia cell line and
human erythroid progenitor cells (45–47). In both cell lines,
thrombin does not trigger either cAMP or calcium responses
on its own, yet it can potentiate Gs-activated increases in intra-
cellular cAMP.Amechanism for this effect of thrombinwas not
reported. Regulation of cAMP plays an important role in cell
growth, differentiation, and cellular functions in the immune
system. Both S1P and thrombin are also known to modulate
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immune responses in various hematopoietic cells (24, 26). Con-
ceivably, the ability of other GPCR pathways to enhance intra-
cellular cAMP responses may help reinforce certain cellular
responses or lead to concerted cellular behaviors. It will be of
interest to determine the downstream targets of enhanced
cAMP responses and their effect on cellular function and
immune function in animals. For example, a major function of
macrophage cells is to produce and release cytokines upon acti-
vation; these processes are strongly modulated by cAMP in the
RAW macrophages and currently under investigation by the
AfCS.
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